Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
21
EVGN Quote, Financials, Valuation and Earnings
Last price:
$0.94
Seasonality move
:
-0.64%
Day range:
$0.96 - $1.01
52-week range:
$0.95 - $2.42
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.36x
P/B ratio:
7.41x
Volume:
87.7K
Avg. volume:
50.7K
1-year change:
-41.19%
Market cap:
$8.5M
Revenue:
$8.5M
EPS (TTM):
-$0.49
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EVGN
Evogene Ltd.
|
$650K | -$0.41 | -82.93% | -68.8% | $2.50 |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -3.23% | -72.97% | $2.50 |
|
MDWD
MediWound Ltd.
|
$6.6M | -$0.83 | 34.91% | -56.27% | $31.50 |
|
NNOX
Nano-X Imaging Ltd.
|
$3.5M | -$0.18 | 33.13% | -35.84% | $8.15 |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-- | -$6.08 | -- | -66.65% | $399.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EVGN
Evogene Ltd.
|
$0.97 | $2.50 | $8.5M | -- | $0.00 | 0% | 1.36x |
|
CANF
Can-Fite BioPharma Ltd.
|
$0.17 | $2.50 | $2.7M | -- | $0.00 | 0% | 0.96x |
|
MDWD
MediWound Ltd.
|
$18.66 | $31.50 | $239.2M | -- | $0.00 | 0% | 9.68x |
|
NNOX
Nano-X Imaging Ltd.
|
$2.78 | $8.15 | $181.8M | -- | $0.00 | 0% | 14.25x |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | $0.00 | 0% | -- |
|
PHGE
BiomX, Inc.
|
$2.00 | $399.00 | $3.1M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EVGN
Evogene Ltd.
|
68.82% | 0.844 | 9.67% | 4.01x |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | 0.899 | -- | -- |
|
MDWD
MediWound Ltd.
|
15.68% | 1.241 | 4.04% | 2.48x |
|
NNOX
Nano-X Imaging Ltd.
|
4.79% | 0.676 | 3.26% | 3.82x |
|
NSRX
Nasus Pharma
|
-- | 0.000 | -- | -- |
|
PHGE
BiomX, Inc.
|
38.57% | 0.072 | 20.14% | 1.51x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EVGN
Evogene Ltd.
|
-$126K | -$2.7M | -57.78% | -66.95% | -870.19% | -$3.8M |
|
CANF
Can-Fite BioPharma Ltd.
|
-- | -- | -- | -- | -- | -- |
|
MDWD
MediWound Ltd.
|
$896K | -$6.5M | -49.92% | -61.71% | -120.19% | -$3.7M |
|
NNOX
Nano-X Imaging Ltd.
|
-$3M | -$14.2M | -31.33% | -32.75% | -412.88% | -$13.9M |
|
NSRX
Nasus Pharma
|
-- | -- | -- | -- | -- | -- |
|
PHGE
BiomX, Inc.
|
-$1.2M | -$8.5M | -116.24% | -160.84% | -- | -$7.2M |
Evogene Ltd. vs. Competitors
-
Which has Higher Returns EVGN or CANF?
Can-Fite BioPharma Ltd. has a net margin of -874.68% compared to Evogene Ltd.'s net margin of --. Evogene Ltd.'s return on equity of -66.95% beat Can-Fite BioPharma Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital EVGNEvogene Ltd.-40.39% $0.44 $19.8M CANFCan-Fite BioPharma Ltd.-- -- -- -
What do Analysts Say About EVGN or CANF?
Evogene Ltd. has a consensus price target of $2.50, signalling upside risk potential of 157.63%. On the other hand Can-Fite BioPharma Ltd. has an analysts' consensus of $2.50 which suggests that it could grow by 1357.73%. Given that Can-Fite BioPharma Ltd. has higher upside potential than Evogene Ltd., analysts believe Can-Fite BioPharma Ltd. is more attractive than Evogene Ltd..
Company Buy Ratings Hold Ratings Sell Ratings EVGNEvogene Ltd.1 0 0 CANFCan-Fite BioPharma Ltd.1 1 0 -
Is EVGN or CANF More Risky?
Evogene Ltd. has a beta of 1.369, which suggesting that the stock is 36.947% more volatile than S&P 500. In comparison Can-Fite BioPharma Ltd. has a beta of 0.982, suggesting its less volatile than the S&P 500 by 1.756%.
-
Which is a Better Dividend Stock EVGN or CANF?
Evogene Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Can-Fite BioPharma Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evogene Ltd. pays -- of its earnings as a dividend. Can-Fite BioPharma Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EVGN or CANF?
Evogene Ltd. quarterly revenues are $312K, which are larger than Can-Fite BioPharma Ltd. quarterly revenues of --. Evogene Ltd.'s net income of -$2.7M is higher than Can-Fite BioPharma Ltd.'s net income of --. Notably, Evogene Ltd.'s price-to-earnings ratio is -- while Can-Fite BioPharma Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evogene Ltd. is 1.36x versus 0.96x for Can-Fite BioPharma Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EVGNEvogene Ltd.1.36x -- $312K -$2.7M CANFCan-Fite BioPharma Ltd.0.96x -- -- --
-
Which has Higher Returns EVGN or MDWD?
MediWound Ltd. has a net margin of -874.68% compared to Evogene Ltd.'s net margin of -48.85%. Evogene Ltd.'s return on equity of -66.95% beat MediWound Ltd.'s return on equity of -61.71%.
Company Gross Margin Earnings Per Share Invested Capital EVGNEvogene Ltd.-40.39% $0.44 $19.8M MDWDMediWound Ltd.16.5% -$0.24 $59.5M -
What do Analysts Say About EVGN or MDWD?
Evogene Ltd. has a consensus price target of $2.50, signalling upside risk potential of 157.63%. On the other hand MediWound Ltd. has an analysts' consensus of $31.50 which suggests that it could grow by 68.81%. Given that Evogene Ltd. has higher upside potential than MediWound Ltd., analysts believe Evogene Ltd. is more attractive than MediWound Ltd..
Company Buy Ratings Hold Ratings Sell Ratings EVGNEvogene Ltd.1 0 0 MDWDMediWound Ltd.5 0 0 -
Is EVGN or MDWD More Risky?
Evogene Ltd. has a beta of 1.369, which suggesting that the stock is 36.947% more volatile than S&P 500. In comparison MediWound Ltd. has a beta of 0.069, suggesting its less volatile than the S&P 500 by 93.055%.
-
Which is a Better Dividend Stock EVGN or MDWD?
Evogene Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MediWound Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evogene Ltd. pays -- of its earnings as a dividend. MediWound Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EVGN or MDWD?
Evogene Ltd. quarterly revenues are $312K, which are smaller than MediWound Ltd. quarterly revenues of $5.4M. Evogene Ltd.'s net income of -$2.7M is lower than MediWound Ltd.'s net income of -$2.7M. Notably, Evogene Ltd.'s price-to-earnings ratio is -- while MediWound Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evogene Ltd. is 1.36x versus 9.68x for MediWound Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EVGNEvogene Ltd.1.36x -- $312K -$2.7M MDWDMediWound Ltd.9.68x -- $5.4M -$2.7M
-
Which has Higher Returns EVGN or NNOX?
Nano-X Imaging Ltd. has a net margin of -874.68% compared to Evogene Ltd.'s net margin of -396.98%. Evogene Ltd.'s return on equity of -66.95% beat Nano-X Imaging Ltd.'s return on equity of -32.75%.
Company Gross Margin Earnings Per Share Invested Capital EVGNEvogene Ltd.-40.39% $0.44 $19.8M NNOXNano-X Imaging Ltd.-86.42% -$0.21 $164.6M -
What do Analysts Say About EVGN or NNOX?
Evogene Ltd. has a consensus price target of $2.50, signalling upside risk potential of 157.63%. On the other hand Nano-X Imaging Ltd. has an analysts' consensus of $8.15 which suggests that it could grow by 193.17%. Given that Nano-X Imaging Ltd. has higher upside potential than Evogene Ltd., analysts believe Nano-X Imaging Ltd. is more attractive than Evogene Ltd..
Company Buy Ratings Hold Ratings Sell Ratings EVGNEvogene Ltd.1 0 0 NNOXNano-X Imaging Ltd.4 0 0 -
Is EVGN or NNOX More Risky?
Evogene Ltd. has a beta of 1.369, which suggesting that the stock is 36.947% more volatile than S&P 500. In comparison Nano-X Imaging Ltd. has a beta of 1.070, suggesting its more volatile than the S&P 500 by 6.959%.
-
Which is a Better Dividend Stock EVGN or NNOX?
Evogene Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nano-X Imaging Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evogene Ltd. pays -- of its earnings as a dividend. Nano-X Imaging Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EVGN or NNOX?
Evogene Ltd. quarterly revenues are $312K, which are smaller than Nano-X Imaging Ltd. quarterly revenues of $3.4M. Evogene Ltd.'s net income of -$2.7M is higher than Nano-X Imaging Ltd.'s net income of -$13.7M. Notably, Evogene Ltd.'s price-to-earnings ratio is -- while Nano-X Imaging Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evogene Ltd. is 1.36x versus 14.25x for Nano-X Imaging Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EVGNEvogene Ltd.1.36x -- $312K -$2.7M NNOXNano-X Imaging Ltd.14.25x -- $3.4M -$13.7M
-
Which has Higher Returns EVGN or NSRX?
Nasus Pharma has a net margin of -874.68% compared to Evogene Ltd.'s net margin of --. Evogene Ltd.'s return on equity of -66.95% beat Nasus Pharma's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital EVGNEvogene Ltd.-40.39% $0.44 $19.8M NSRXNasus Pharma-- -- -- -
What do Analysts Say About EVGN or NSRX?
Evogene Ltd. has a consensus price target of $2.50, signalling upside risk potential of 157.63%. On the other hand Nasus Pharma has an analysts' consensus of -- which suggests that it could fall by --. Given that Evogene Ltd. has higher upside potential than Nasus Pharma, analysts believe Evogene Ltd. is more attractive than Nasus Pharma.
Company Buy Ratings Hold Ratings Sell Ratings EVGNEvogene Ltd.1 0 0 NSRXNasus Pharma0 0 0 -
Is EVGN or NSRX More Risky?
Evogene Ltd. has a beta of 1.369, which suggesting that the stock is 36.947% more volatile than S&P 500. In comparison Nasus Pharma has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock EVGN or NSRX?
Evogene Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nasus Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evogene Ltd. pays -- of its earnings as a dividend. Nasus Pharma pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EVGN or NSRX?
Evogene Ltd. quarterly revenues are $312K, which are larger than Nasus Pharma quarterly revenues of --. Evogene Ltd.'s net income of -$2.7M is higher than Nasus Pharma's net income of --. Notably, Evogene Ltd.'s price-to-earnings ratio is -- while Nasus Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evogene Ltd. is 1.36x versus -- for Nasus Pharma. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EVGNEvogene Ltd.1.36x -- $312K -$2.7M NSRXNasus Pharma-- -- -- --
-
Which has Higher Returns EVGN or PHGE?
BiomX, Inc. has a net margin of -874.68% compared to Evogene Ltd.'s net margin of --. Evogene Ltd.'s return on equity of -66.95% beat BiomX, Inc.'s return on equity of -160.84%.
Company Gross Margin Earnings Per Share Invested Capital EVGNEvogene Ltd.-40.39% $0.44 $19.8M PHGEBiomX, Inc.-- -$5.55 $17.1M -
What do Analysts Say About EVGN or PHGE?
Evogene Ltd. has a consensus price target of $2.50, signalling upside risk potential of 157.63%. On the other hand BiomX, Inc. has an analysts' consensus of $399.00 which suggests that it could grow by 8150%. Given that BiomX, Inc. has higher upside potential than Evogene Ltd., analysts believe BiomX, Inc. is more attractive than Evogene Ltd..
Company Buy Ratings Hold Ratings Sell Ratings EVGNEvogene Ltd.1 0 0 PHGEBiomX, Inc.1 0 0 -
Is EVGN or PHGE More Risky?
Evogene Ltd. has a beta of 1.369, which suggesting that the stock is 36.947% more volatile than S&P 500. In comparison BiomX, Inc. has a beta of 1.558, suggesting its more volatile than the S&P 500 by 55.818%.
-
Which is a Better Dividend Stock EVGN or PHGE?
Evogene Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BiomX, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evogene Ltd. pays -- of its earnings as a dividend. BiomX, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EVGN or PHGE?
Evogene Ltd. quarterly revenues are $312K, which are larger than BiomX, Inc. quarterly revenues of --. Evogene Ltd.'s net income of -$2.7M is higher than BiomX, Inc.'s net income of -$9.2M. Notably, Evogene Ltd.'s price-to-earnings ratio is -- while BiomX, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evogene Ltd. is 1.36x versus -- for BiomX, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EVGNEvogene Ltd.1.36x -- $312K -$2.7M PHGEBiomX, Inc.-- -- -- -$9.2M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
14
SMX alert for Dec 30
SMX (Security Matters) Plc [SMX] is down 40.26% over the past day.
Buy
71
ZCSH alert for Dec 30
Grayscale Zcash Trust (ZEC) [ZCSH] is down 4.56% over the past day.
Buy
69
GDXU alert for Dec 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 3.19% over the past day.
